Artiva Biotherapeutics, Inc.
ARTV$143M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSAN DIEGO106 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ARTV News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Allogeneic NK Cells | Phase 2 | Refractory Rheumatoid Arthritis (RA) | - | - |
AB-101 | Phase 2 | Non Hodgkin Lymphoma | - | - |
Refractory Rheumatoid Arthritis (RA)
1 drug in this indication
Non Hodgkin Lymphoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply